KRAS Cancer Research Results

KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog: Click to Expand ⟱
Source: CGL-Driver Genes
Type: Oncogene
KRAS (Kirsten rat sarcoma viral oncogene homolog) is a gene that encodes a protein involved in cell signaling pathways that control cell growth and division. Mutations in the KRAS gene are among the most common genetic alterations found in various types of cancer, particularly pancreatic, colorectal, and lung cancers.
Mutations in the KRAS gene lead to the production of a hyperactive KRAS protein.
Cancers with KRAS mutations are often more aggressive and associated with poorer prognosis.
Scientific Papers found: Click to Expand⟱
5404- ASA,    Low-Dose Aspirin and Prevention of Colorectal Cancer: Evidence From a Nationwide Registry-Based Cohort in Norway
- Study, CRC, NA
Risk↓, other↝, Dose↝, Risk↓, other↓, other↝, KRAS↓, other↓, other↓,
5968- CET,    Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer
- in-vitro, CRC, NA
eff↑, Half-Life↑, Half-Life↑, EGFR↓, OS↑, QoL↑, eff↑, KRAS↓,
669- EGCG,    Epigallocatechin-3-gallate and cancer: focus on the role of microRNAs
- Review, NA, NA
Let-7↑, KRAS↓,
6385- Eug,    Anticancer potential of eugenol in hepatocellular carcinoma through modulation of oxidative stress, inflammation, apoptosis, and proliferation mechanisms
- in-vivo, HCC, HepG2
tumCV↓, TumCMig↓, *ALAT↓, *AST↓, *ALP↓, *Bil↓, *CEA↓, *lipid-P↓, *TNF-α↓, *IL1β↓, NF-kB↓, CXCR3↓, HRAS↓, KRAS↓, Ki-67↓, *GSH↑, *GPx↑, *SOD↑, *NRF2↑, P53↑, BAX↑, DR4↑, DR5↑,
6341- Eug,    A Metabolomic Investigation of Eugenol on Colorectal Cancer Cell Line HT-29 by Modifying the Expression of APC, p53, and KRAS Genes
- NA, Colon, HT29
*antiOx↑, ROS↑, tumCV↓, P53↑, APC↑, KRAS↓, FAO↓, Glycolysis↓,
5254- NCL,    The magic bullet: Niclosamide
- Review, Var, NA
Wnt↓, β-catenin/ZEB1↓, RAS↓, STAT3↓, NOTCH↓, E2Fs↓, mTOR↓, eff↑, PD-1↓, PD-L1↓, BioAv↝, toxicity↓, BioAv↑, ETC↑, NADH:NAD↓, TCA↑, Warburg↓, Diff↑, AMPK↑, P53↑, PP2A↑, HIF-1↓, KRAS↓, Myc↓, RadioS↑, ChemoSen↑, Dose↝, Dose↑,
3343- QC,    Quercetin, a Flavonoid with Great Pharmacological Capacity
- Review, Var, NA - Review, AD, NA - Review, Arthritis, NA
*antiOx↑, *ROS↓, *angioG↓, *Inflam↓, *BioAv↓, *Half-Life↑, *GSH↑, *SOD↑, *Catalase↑, *Nrf1↑, *BP↓, *cardioP↑, *IL10↓, *TNF-α↓, *Aβ↓, *GSK‐3β↓, *tau↓, *neuroP↑, *Pain↓, *COX2↓, *NRF2↑, *HO-1↑, *IL1β↓, *IL17↓, *MCP1↓, PKCδ↓, ERK↓, BAX↓, cMyc↓, KRAS↓, ROS↓, selectivity↑, tumCV↓, Apoptosis↑, TumCCA↑, eff↑, P-gp↓, eff↑, eff↑, eff↑, eff↑, CycB/CCNB1↓, CDK1↓, CDK4↓, CDK2↓, TOP2↓, Cyt‑c↑, cl‑PARP↑, MMP↓, HSP70/HSPA5↓, HSP90↓, MDM2↓, RAS↓, eff↑,

Showing Research Papers: 1 to 7 of 7

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned ⓘ

CXCR3↓, 1,  

Redox & Oxidative Stress ⓘ

ROS↓, 1,   ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

ETC↑, 1,   MMP↓, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   cMyc↓, 1,   FAO↓, 1,   Glycolysis↓, 1,   NADH:NAD↓, 1,   TCA↑, 1,   Warburg↓, 1,  

Cell Death ⓘ

Apoptosis↑, 1,   BAX↓, 1,   BAX↑, 1,   Cyt‑c↑, 1,   DR4↑, 1,   DR5↑, 1,   MDM2↓, 1,   Myc↓, 1,  

Transcription & Epigenetics ⓘ

other↓, 3,   other↝, 2,   tumCV↓, 3,  

Protein Folding & ER Stress ⓘ

HSP70/HSPA5↓, 1,   HSP90↓, 1,  

DNA Damage & Repair ⓘ

P53↑, 3,   cl‑PARP↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   CDK2↓, 1,   CDK4↓, 1,   CycB/CCNB1↓, 1,   E2Fs↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

Diff↑, 1,   ERK↓, 1,   HRAS↓, 1,   Let-7↑, 1,   mTOR↓, 1,   NOTCH↓, 1,   RAS↓, 2,   STAT3↓, 1,   TOP2↓, 1,   Wnt↓, 1,  

Migration ⓘ

APC↑, 1,   Ki-67↓, 1,   KRAS↓, 7,   PKCδ↓, 1,   TumCMig↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

EGFR↓, 1,   HIF-1↓, 1,  

Barriers & Transport ⓘ

P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

NF-kB↓, 1,   PD-1↓, 1,   PD-L1↓, 1,  

Protein Aggregation ⓘ

PP2A↑, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,   BioAv↝, 1,   ChemoSen↑, 1,   Dose↑, 1,   Dose↝, 2,   eff↑, 9,   Half-Life↑, 2,   RadioS↑, 1,   selectivity↑, 1,  

Clinical Biomarkers ⓘ

EGFR↓, 1,   Ki-67↓, 1,   KRAS↓, 7,   Myc↓, 1,   PD-L1↓, 1,  

Functional Outcomes ⓘ

OS↑, 1,   QoL↑, 1,   Risk↓, 2,   toxicity↓, 1,  
Total Targets: 74

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 2,   Bil↓, 1,   Catalase↑, 1,   GPx↑, 1,   GSH↑, 2,   HO-1↑, 1,   lipid-P↓, 1,   Nrf1↑, 1,   NRF2↑, 2,   ROS↓, 1,   SOD↑, 2,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

GSK‐3β↓, 1,  

Migration ⓘ

CEA↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IL10↓, 1,   IL17↓, 1,   IL1β↓, 2,   Inflam↓, 1,   MCP1↓, 1,   TNF-α↓, 2,  

Synaptic & Neurotransmission ⓘ

tau↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   Half-Life↑, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   ALP↓, 1,   AST↓, 1,   Bil↓, 1,   BP↓, 1,   CEA↓, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,   neuroP↑, 1,   Pain↓, 1,  
Total Targets: 35

Scientific Paper Hit Count for: KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
2 Eugenol
1 Aspirin
1 cetuximab
1 EGCG (Epigallocatechin Gallate)
1 Niclosamide (Niclocide)
1 Quercetin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:174  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page